{
  "profile_url": "https://www.moffitt.org/research-science/researchers/jeffrey-lancet",
  "last_updated": "2025-10-19T00:28:05.444649",
  "researcher_id": "3177",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "Malignant Hematology",
  "research_program": "Molecular Medicine Program",
  "overview": "Dr. Lancet is nationally and internationally recognized for his clinical research in the field of acute leukemias, where he has developed a special interest in the design and conduct of early phase clinical trials in acute myeloid leukemia and related malignancies.",
  "research_interests": [
    "Dr. Lancet\u2019s work on novel therapies in AML, including soon to be approved drugs such as CPX-351 and Vosaroxin, has been published extensively in high-level journals. He also has a special interest in the treatment of older adults with leukemia, and is the clinical leader and co-investigator on a large National Cancer Institute grant that focuses on treatment decision models for these patients. Dr. Lancet has received funding for his clinical trials through the National Cancer Institute and industry sponsors. In addition, Dr. Lancet was one of the original recipients of the prestigious National Cancer Institute Clinical Investigator Team Leadership Award.\n  *"
  ],
  "associations": [
    "Malignant Hematology",
    "Drug Discovery",
    "Molecular Medicine Program",
    "Experimental Therapeutics Program"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "SUNY Upstate Medical College",
      "degree": "MD"
    },
    {
      "type": "Internship",
      "institution": "Strong Memorial Hospital, Rochester School of Medicine & Dentistry",
      "position": "Intern"
    },
    {
      "type": "Residency",
      "institution": "Strong Memorial Hospital, Rochester School of Medicine & Dentistry",
      "position": "Intern",
      "specialty": "al Medicine"
    },
    {
      "type": "Residency",
      "institution": "St. Mary's Hospital, Rochester School of Medicine & Dentistry",
      "position": "Resident",
      "specialty": "& Instructor in Medicine"
    },
    {
      "type": "Fellowship",
      "institution": "Rochester School of Medicine & Dentistry",
      "specialty": "Hematology/Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Hematology"
    }
  ],
  "publications": [
    {
      "title": "Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clin Lymphoma Myeloma Leuk",
      "pubmed_id": "40254502",
      "year": "2025",
      "journal": "25(9):661-671",
      "authors": ""
    },
    {
      "title": "Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda DM, Padron E, Sweet K, Sallman DA, Lancet J, Carraway HE, Watts J, Zeidan A, Pollyea DA, Komrokji RS. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (\u2265 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. Am J Hematol",
      "pubmed_id": "40772639",
      "year": "2025",
      "journal": "100(10):1920-1923",
      "authors": ""
    },
    {
      "title": "Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS. Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Blood Neoplasia",
      "pubmed_id": "40453136",
      "pmc_id": "PMC12067887",
      "year": "2025",
      "journal": "2(2):100062",
      "authors": ""
    },
    {
      "title": "Komrokji Z, Ali NA, Xie Z, Chan O, Yun S, Walker A, Lancet J, Kuykendall A, Sallman D, Padron E, Komrokji RS. Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML). Leuk Res",
      "pubmed_id": "39921921",
      "year": "2025",
      "journal": "150:107662",
      "authors": ""
    },
    {
      "title": "Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahm\u00e9 R, Winer ES, Lehmann-Che J, Roboz GJ, Madelaine I, Sekeres MA, Peterlin P, Chan O, Beyne-Rauzy O, Kuykendall A, Recher C, McLemore A, Stamatoullas A, Zhang L, Willems L, Mo Q, Raffoux E, Nardelli L, Berthon C, Al Ali NH, Quesnel B, Padron E, Kantarjian HM, List AF, Ades L, Lancet JE, Fenaux P, Cluzeau T. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. Hemasphere",
      "pubmed_id": "40657305",
      "pmc_id": "PMC12255903",
      "year": "2025",
      "journal": "9(7):e70164",
      "authors": ""
    },
    {
      "title": "Komrokji RS, Ammad-Ud-Din M, Ali NHA, Xie Z, Chan O, Kuykendall AT, Yun S, Walker AR, Lancet J, Padron E, Sallman DA. Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival. Clin Lymphoma Myeloma Leuk",
      "pubmed_id": "40113545",
      "year": "2025",
      "journal": "25(7):e487-e490",
      "authors": ""
    },
    {
      "title": "Jain AG, Volpe VO, Wang C, Ball S, Tobon K, Chan O, Padron E, Kuykendall A, Lancet JE, Komrokji R, Sallman DA, Sweet KL. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Ann Hematol",
      "pubmed_id": "39243312",
      "year": "2025",
      "journal": "104(1):307-315",
      "authors": ""
    },
    {
      "title": "Consagra A, Lanino L, Al Ali NH, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi MG, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman DA, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta MG, Santini V, Komrokji RS. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. Hemasphere",
      "pubmed_id": "39944234",
      "pmc_id": "PMC11814532",
      "year": "2025",
      "journal": "9(2):e70086",
      "authors": ""
    },
    {
      "title": "Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carr\u00e9 M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, R\u00e9cher C. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol",
      "pubmed_id": "38899566",
      "year": "2024",
      "journal": "99(10):1870-1876",
      "authors": ""
    },
    {
      "title": "Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, Mishra A, Sweet K, Perez L, Ochoa-Bayona J, Nieder M, Komrokji R, Lancet J, Fernandez H, Nishihori T, Pidala J, Anasetti C, Bejanyan N. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplant Cell Ther",
      "pubmed_id": "39147136",
      "year": "2024",
      "journal": "30(11):1090",
      "authors": ""
    }
  ],
  "grants": [
    {
      "description": "Title: North American Star Consortium  \nAward Number: 4UM1CA186644-08  \nSponsor: National Cancer Institute (NCI)  \nLancet, J. (PD/PI)",
      "source": "NCI",
      "period": "6644-08"
    }
  ],
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/LancetJeffrey_3177.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=3177"
  },
  "content_hash": "790bc2d5a59e967cf680720fbd71a4e981a512bd2c8b830be69f9f073df6a7a3",
  "researcher_name": "Jeffrey Lancet",
  "department": "Drug Discovery"
}